SARS-CoV-2 nucleocapsid protein directly prevents cGAS-DNA recognition through competitive binding
- PMID: 40549905
- PMCID: PMC12232725
- DOI: 10.1073/pnas.2426204122
SARS-CoV-2 nucleocapsid protein directly prevents cGAS-DNA recognition through competitive binding
Abstract
A hallmark of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is the delayed interferon response. Interferons are typically produced upon host recognition of pathogen- or damage-associated molecular patterns, such as nucleic acids. While the mechanisms by which SARS-CoV-2 evades host recognition of its RNA are well studied, how it evades immune responses to cytosolic DNA-leaked from mitochondria or nuclei during infection-remains poorly understood. Here, we demonstrate that the SARS-CoV-2 nucleocapsid protein directly suppresses DNA sensing by cyclic guanosine monophosphate-adenosine monophosphate synthase (cGAS). Although primarily known for packaging the viral RNA genome, we uncover that the SARS-CoV-2 nucleocapsid protein also binds DNA with high affinity and competitively blocks cGAS activation. Using cell-free biochemical and biophysical approaches, including single-molecule optical tweezers, we show that the nucleocapsid protein binds to DNA at nanomolar concentrations and cocondenses with DNA at micromolar concentrations, thereby impeding stable cGAS-DNA interactions required for signal propagation. Hyperphosphorylation of the nucleocapsid protein diminishes its competitive binding capacity. Our findings reveal an unexpected role of the SARS-CoV-2 nucleocapsid protein in directly suppressing the cGAS-STING pathway, strongly suggesting that this contributes to the delayed interferon response during infection. This study raises the possibility that nucleocapsid proteins of other RNA viruses may also exhibit moonlighting functions by antagonizing host nucleic acid-sensing pathways.
Keywords: biomolecular condensates; cGAS; coronavirus; innate immune system; nucleocapsid protein.
Conflict of interest statement
Competing interests statement:A.A.H. is a founder of and consultant for Dewpoint Therapeutics Inc. The company was not involved in the work of this manuscript.
Figures





Similar articles
-
SARS-CoV-2 Nucleocapsid Protein Induces Tau Pathological Changes That Can Be Counteracted by SUMO2.Int J Mol Sci. 2024 Jun 28;25(13):7169. doi: 10.3390/ijms25137169. Int J Mol Sci. 2024. PMID: 39000276 Free PMC article.
-
cGAS-mediated autophagy protects the liver from ischemia-reperfusion injury independently of STING.Am J Physiol Gastrointest Liver Physiol. 2018 Jun 1;314(6):G655-G667. doi: 10.1152/ajpgi.00326.2017. Epub 2018 Feb 15. Am J Physiol Gastrointest Liver Physiol. 2018. PMID: 29446653 Free PMC article.
-
Screening and identification of host factors interacting with the nucleocapsid protein of SARS-CoV-2 omicron variant using the yeast two-hybrid system.BMC Microbiol. 2025 Aug 1;25(1):474. doi: 10.1186/s12866-025-04226-7. BMC Microbiol. 2025. PMID: 40751130 Free PMC article.
-
Physical interventions to interrupt or reduce the spread of respiratory viruses.Cochrane Database Syst Rev. 2023 Jan 30;1(1):CD006207. doi: 10.1002/14651858.CD006207.pub6. Cochrane Database Syst Rev. 2023. PMID: 36715243 Free PMC article.
-
Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19.Cochrane Database Syst Rev. 2022 May 20;5(5):CD013665. doi: 10.1002/14651858.CD013665.pub3. Cochrane Database Syst Rev. 2022. PMID: 35593186 Free PMC article.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous